By 01/17/2012 | Press Release
GREENWOOD VILLAGE, Colo., Jan. 17, 2012 /PRNewswire/ -- Ampio Pharmaceuticals, Inc. (NASDAQ: AMPE - News) ("Ampio" or the "Company"), a company that discovers and develops new uses for previously approved drugs and new molecular entities ("NMEs"), will hold a webcast on Thursday, January 26, 2012, at 4:15 p.m. EST. Management will outline the Company's 2012 milestones and will provide a detailed review for each of its three lead products.
Dial-in Information
United States: 866.314.5232
International: 617.213.8052
Passcode: 42025023
The call also can be accessed at www.ampiopharma.com.
Replay Information
United States: 888 286.8010
International: 617 801.6888
Passcode: 97542504
The replay will be posted approximately two hours after the completion of the live event, and it will be available for 30 days. Ampio will post a replay of the January 26, 2012, call on its website.
About Ampio Pharmaceuticals
Ampio Pharmaceuticals, Inc. develops innovative proprietary
drugs for metabolic disease, eye disease, kidney disease,
inflammation, CNS disease, and male sexual dysfunction. The
product pipeline includes new uses for previously approved
drugs and new molecular entities ("NMEs"). By
concentrating on development of new uses for previously
approved drugs, approval timelines, costs and risk of
clinical failure are reduced because these drugs have
strong potential to be safe and effective while their
shorter development times can significantly increase near
term value. A key strategy includes actively exploring
partnership, licensing and other collaboration
opportunities to maximize Ampio's product development
programs. For more information about Ampio, please visit
our website, .
Forward-Looking Statements
Ampio's statements made in this press release that are
not historical fact and that relate to future plans or
events are forward-looking statements within the meaning of
the Private Securities Litigation Reform Act of 1995.
Forward-looking statements can be identified by use of
words such as "believe," "expect,"
"plan," "anticipate," and similar
expressions. These forward-looking statements include risks
associated with clinical trials, expected results,
regulatory approvals, and changes in business conditions
and similar events. The risks and uncertainties involved
include those detailed from time to time in Ampio's
filings with the Securities and Exchange Commission,
including Ampio's Annual Report on Form 10-K and
Quarterly Reports on Form 10-Q.
Contact
Investor Relations,
